Severe cases of coronavirus disease 2019 (COVID‐19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of pro‐inflammatory cytokines that are thought to be a major drivers of morbidity and mortality for these patients.[^1^](#bjh16863-bib-0001){ref-type="ref"} Several drugs with anti‐inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID‐19, and several clinical trials are underway ([ClinicalTrials.gov](https://ClinicalTrials.gov) Identifier: NCT04315298, NCT04317092, NCT04306705).

The Bruton tyrosine kinase inhibitors (BTKi) ibrutinib, acalabrutinib and zanubrutinib are commonly used to treat chronic lymphocytic leukaemia (CLL), Waldenström macroglobulinaemia (WM), and chronic graft‐*versus*‐host disease (GvHD) and have been shown to have potent anti‐inflammatory effects resulting in decreased levels of pro‐inflammatory cytokines that are commonly elevated in severe COVID‐19.[^2^](#bjh16863-bib-0002){ref-type="ref"} Furthermore, these drugs may abate some noxious pulmonary effects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and other similar viruses, reducing the degree of lung injury and disease‐related mortality.[^3^](#bjh16863-bib-0003){ref-type="ref"} ^,^ [^4^](#bjh16863-bib-0004){ref-type="ref"} Clinical trials examining the potential benefit of BTKi in COVID‐19 are underway ([ClinicalTrials.gov](https://ClinicalTrials.gov) Identifier: NCT04382586, NCT04346199).

A recent study[^5^](#bjh16863-bib-0005){ref-type="ref"} described the outcomes of six patients with COVID‐19 with WM receiving ibrutinib. Five of the six had mild symptoms, did not require hospitalisation, and recovered promptly. One of the six required hospitalisation and mechanical ventilation but eventually recovered fully. Acknowledging the limitations of this small study, the authors hypothesised that ibrutinib may protect against lung injury in patients infected with SARS‐CoV‐2, and therefore suggest BTKi continuation in patients with WM with COVID‐19.

It is unclear if the proposed protective effect of BTKi applies to patients with CLL, who have immune deregulation secondary to the underlying disease process.[^6^](#bjh16863-bib-0006){ref-type="ref"} Also, BTKi use in CLL is associated with increased risk of infection, especially viral.[^7^](#bjh16863-bib-0007){ref-type="ref"} Considering the high prevalence of CLL, studying outcomes of BTKi in patients with CLL with COVID‐19 and exploring whether to continue BTKi in this setting becomes highly relevant. We reviewed our institutional experience with this population, examining severity of disease and clinical outcomes. Our present study was approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai.

Eight patients with CLL receiving a BTKi were hospitalised for COVID‐19 within our healthcare system (seven ibrutinib, one acalabrutinib). The clinical characteristics of the patients are summarised in Table [I](#bjh16863-tbl-0001){ref-type="table"}.[^5^](#bjh16863-bib-0005){ref-type="ref"} The median (range) age was 72 (49--88) years. BTKi was held in six of the eight patients ('BTKi‐held') and continued in two ('BTKi‐cont'). Two of the eight patients in the 'BTKi‐held' cohort developed severe respiratory failure and eventually died (*Patient 6*: ibrutinib for 3+ years, full dose of 420 mg daily, *Patient 3*: ibrutinib for \<4 months, recommended reduced dose of 140 mg due to concomitant use of a strong cytochrome P450 3A4 \[CYP3A4\] inhibitor). All others had mild‐to‐moderate disease.

###### 

Baseline characteristics of eight patients with B‐cell diagnoses on BTKi with COVID‐19 infection.

                                       BTKi‐held   BTKi‐continued                                                                   
  ------------------------------------ ----------- ---------------- ----------- --------------- ----------- ----------- ----------- -----------
  **Demographics**                                                                                                                  
  Age, years                           72          67               88          49              72          80          56          75
  Gender                               M           M                M           M               M           M           M           F
  Race/ethnicity                       NHB         Unknown          NHW         NHW             NHW         NHW         Unknown     Unknown
  **Comorbidities**                                                                                                                 
  Obesity\[BMI \> 30 kg/m^2^\]         N           Y                N           N               Y           N           Y           N
  Hypertension                         Y           Y                Y           N               Y           Y           N           N
  Diabetes                             N           Y                N           N               Y           Y           Y           N
  Hyperlipidaemia                      N           N                Y           N               N           N           N           N
  History of ASCVD                     Y           N                N           N               Y           N           N           N
  **CLL disease characteristics**                                                                                                   
  BTKi                                 Ibrutinib   Ibrutinib        Ibrutinib   Acalabrutinib   Ibrutinib   Ibrutinib   Ibrutinib   Ibrutinib
  Dose of BTKi, mg/day                 140^++^     420              140\*       200             420         420         420         420
  Time on BTKi, months                 NA          18·9             3·8         16·1            NA          44·9        29·6        18·1
  IVIG in last month                   NA          N                N           N               NA          NA          Y           N
  Normal IgG                           NA          NA               Y           NA              NA          NA          Y           N
  **COVID‐19 presentation**                                                                                                         
  CLL Diagnosis to COVID‐19 (months)   70·2        56·5             173·2       111·5           NA          68·5        78·7        106·9
  Cough                                Y           Y                Y           Y               N           N           Y           N
  Fever                                Y           Y                Y           Y               N           Y           Y           Y
  Dyspnea                              Y           Y                N           N               N           Y           N           N
  Sore throat                          N           Y                N           N               N           N           N           Y
  Fatigue                              N           Y                N           Y               N           N           Y           Y
  Ageusia                              N           N                N           N               N           N           Y           N
  Anosmia                              N           N                N           N               N           N           Y           N
  **Data at COVID‐19 diagnosis**                                                                                                    
  WBC, K/µl                            4·9         10·9             28·1        8·3             7·3         9·5         34·0        7·2
  ALC, K/µl                            1·2         0·9              10·3        4·4             1·7         2·1         21·7        0·8
  Hb, g/l                              134         152              88          151             134         152         135         140
  Platelet count, K/µl                 145         170              167         150             91          181         207         151
  C‐reactive protein, mg/l             81·3        294              283·7       2·1             62·5        124·9       59·1        1·5
  Ferritin, ng/ml                      13,401      1,095            295         NA              NA          1,113       158         NA
  D‐dimer, mlFEU                       3·0         5·63             \>20        NA              NA          3·08        0·4         0·28
  IL‐1β, pg/ml                         NA          0·7              0·5         NA              NA          NA          \<0·3       \<0·3
  IL‐6, pg/ml                          NA          87·3             53·0        NA              NA          NA          43·2        7·2
  IL‐8, pg/ml                          NA          24·8             18·0        NA              NA          NA          46·7        15·4
  TNF‐α, pg/ml                         NA          34·8             100·0       NA              NA          NA          22·0        16·7
  Multifocal pneumonia                 No          No               No          No              Yes         Yes         No          No
  **COVID‐19 outcomes**                                                                                                             
  Hospitalisation                      Y           Y                Y           Y               Y           Y           Y           Y
  Length of stay, days                 10          7                9           5               8           19          9           3
  Max. oxygen requirement              NC          NC               HFNC        None            None        BIPAP       NC          None
  COVID‐19 treatment                   HC, AZ      HC               HC          HC, AZ, TOCI    HC, AZ      HC, AZ      HC          None
  Death                                N           N                Y           N               N           Y           N           N

M, male; F, female; NHB, non‐hispanic black; NHW, non‐hispanic white; ASCVD, atherosclerotic cardiovascular disease; CLL, chronic lymphocytic leukaemia; WM, Waldenström macroglobulinaemia; IVIG, intravenous immunoglobulin; IgG, immunoglobulin G; WBC, white blood cell count; ALC, absolute lymphocyte count; Hb, haemoglobin; IL, interleukin; TNF, tumor necrosis factor; NC, nasal cannula; HFNC, high‐flow nasal cannula; HC, hydroxychloroquine; AZ, azithromycin; TOCI, tocilizumab; ST, steroids, NA, not available. \*Dose‐reduced due to concomitant use of strong a CYP3A4 inhibitor; ++Reason for dose reduction unclear.

Our observations support continuation of BTKi in patients with CLL throughout COVID‐19 infection, as they may provide some protection against noxious viral effects. Our findings concur with Treon *et al*.[^5^](#bjh16863-bib-0005){ref-type="ref"} in a cohort of patients with WM receiving ibrutinib. We acknowledge the limitations of our present study, namely its retrospective nature and small sample size. Further studies are needed to validate this proposed approach. The results of two clinical trials assessing the effect of zanubrutinib (NCT04382586) and acalabrutinib (NCT04346199) in hospitalised patients with COVID‐19 will help clarify the role of BTKi in this setting.
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Notably, the two patients who continued on ibrutinib had short hospital stays, minimal oxygen requirements, and have since fully recovered. Neither of them developed significant adverse events (AEs) attributable to BTKi.

Discussion {#bjh16863-sec-0002}
==========

The BTK pathway is critical to the production of multiple pro‐inflammatory cytokines. Inhibition of BTK signalling results in decreased cytokine levels, with a subsequent anti‐inflammatory effect[^2^](#bjh16863-bib-0002){ref-type="ref"}. BTK signalling dysregulation in lung macrophages may be a key pathophysiological component of SARS‐CoV‐2‐related lung injury.[^4^](#bjh16863-bib-0004){ref-type="ref"}, [^8^](#bjh16863-bib-0008){ref-type="ref"} In mouse influenza models, use of BTKi successfully rescued mice from lethal acute lung injury.[^3^](#bjh16863-bib-0003){ref-type="ref"} Therefore, BTK pathway inhibition is a promising target to lessen the exaggerated immune response of severe COVID‐19 and its respiratory complications.

Recent studies show high severity of infection in patients with haematological malignancies who contract COVID‐19.[^9^](#bjh16863-bib-0009){ref-type="ref"} Despite the defects in immunity and subsequent infection risk in CLL,[^6^](#bjh16863-bib-0006){ref-type="ref"} six of our eight patients had mild‐to‐moderate disease severity, minimal oxygen requirements, and short hospital stays. The 'BTKi‐cont' cohort had particularly prompt recoveries. Apart from hydroxychloroquine, neither received other therapies that could have contributed to their favourable outcomes. Recognising the limitations of a small sample size, our present findings support those of Treon *et al*.[^5^](#bjh16863-bib-0005){ref-type="ref"}, suggesting that BTKi may indeed have protective effects against SARS‐CoV‐2 virulence.

The 'BTKi‐held' cohort may still have experienced some benefit from being on BTKi at the time of infection. The half‐life of ibrutinib and acalabrutinib with preserved renal function is only 4--7 h, but as BTKi bind covalently to BTK, pathway re‐activation requires *de novo* enzymatic synthesis, which occurs at highly variable rates across patients.[^10^](#bjh16863-bib-0010){ref-type="ref"} Some degree of BTK inhibition may therefore have persisted after drug clearance.

In a document released by the American Society of Hematology (ASH) to provide guidance on CLL management in patients with COVID‐19, experts conclude there is insufficient data to determine whether to continue BTKi in this setting.[^11^](#bjh16863-bib-0011){ref-type="ref"} However, they advise caution with abrupt discontinuation of ibrutinib, which has been associated with a form of withdrawal syndrome resulting in significant cytokine release.[^12^](#bjh16863-bib-0012){ref-type="ref"}

BTKi therapy in CLL increases risk of infections, especially pneumonia.[^13^](#bjh16863-bib-0013){ref-type="ref"} However, incidence of infection is highest in the first 6 months and then decreases over time.[^14^](#bjh16863-bib-0014){ref-type="ref"} Furthermore, long‐term BTKi therapy may allow for meaningful recovery of humoral immune function, ultimately leading to decreased infection rates.[^15^](#bjh16863-bib-0015){ref-type="ref"}

No significant AEs attributable to BTKi were seen in the 'BTKi‐cont' cohort (i.e., haemorrhage, atrial arrhythmias). However, neither of them received full‐dose anti‐coagulation, use of which is becoming increasingly common to target the pro‐thrombotic effects of COVID‐19. BTKi should be used cautiously in this setting.
